Zhx2 expression in the mouse brain

Prescription opioids like oxycodone (OXY; the active component in OxyContin™) continue to drive the ongoing opioid use disorder (OUD) epidemic due to their widespread prescription and distribution. Genetic factors influencing pharmacokinetic and pharmacodynamic properties of opioids can have profound impacts on drug response and, in turn, influence risk for OUD. We previously used quantitative trait locus (QTL) mapping and gene validation to identify zinc-finger homeobox 2 (Zhx2) loss-of-function as a quantitative trait gene and mechanism underlying increased brain concentration of oxymorphone (OMOR) following systemic administration of OXY in BALB/cJ females that was linked to increased OXY reward. To test whether we could rescue the behavioral phenotype, we overexpressed Zhx2 in the brain via retro-orbital injection of a brain-specific adeno-associated virus (AAV). We observed restricted Zhx2 expression (especially females), with more widespread expression in males. Consequently, we did not observe any significant effect of brain Zhx2 overexpression on OXY reward as measured via conditioned place preference (CPP). However, Zhx2 overexpression did protect against OXY-induced weight loss in females following a high-dose OXY regimen. Despite the effect on weight loss, Zhx2 overexpression had no effect on spontaneous or naloxone-precipitated withdrawal behaviors. We then examined native Zhx2 protein expression in the brains of the BALB/cByJ substrain (showing wild-type levels of Zhx2 expression) via immunohistochemical co-localization and found that Zhx2 is mainly expressed in neurons located in key reward, motivational, and emotion-related regions such as the hippocampus (HPC), amygdala, striatum (Str), and cerebellum. To summarize, Zhx2 overexpression via retro-orbital AAV administration was quite limited, yet had significant effects on opioid-induced weight loss. Furthermore, for the first time, we provide anatomical visualization of Zhx2 expression at the protein level in neurons vs. glia throughout multiple brain regions.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.11.765907
Primary Topic
Neurotransmitter Receptor Influence on Behavior
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Zhx2 expression in the mouse brain

Sophia A. Miracle, Camron D. Bryant, Hala Ajjawi, Aleksandra G. Gorelik et al.
bioRxiv (Cold Spring Harbor Laboratory)
Neurotransmitter Receptor Influence on Behavior
preprint

Zhx2 expression in the mouse brain

Sophia A. Miracle, Camron D. Bryant, Hala Ajjawi, Aleksandra G. Gorelik, Ava B. Glavine, Sophia V. Pavlidis, Isabella C. Conti, Erin E. Lynch, Morgan L. Hofmeyer
preprint en

Abstract

Prescription opioids like oxycodone (OXY; the active component in OxyContin™) continue to drive the ongoing opioid use disorder (OUD) epidemic due to their widespread prescription and distribution. Genetic factors influencing pharmacokinetic and pharmacodynamic properties of opioids can have profound impacts on drug response and, in turn, influence risk for OUD. We previously used quantitative trait locus (QTL) mapping and gene validation to identify zinc-finger homeobox 2 (Zhx2) loss-of-function as a quantitative trait gene and mechanism underlying increased brain concentration of oxymorphone (OMOR) following systemic administration of OXY in BALB/cJ females that was linked to increased OXY reward. To test whether we could rescue the behavioral phenotype, we overexpressed Zhx2 in the brain via retro-orbital injection of a brain-specific adeno-associated virus (AAV). We observed restricted Zhx2 expression (especially females), with more widespread expression in males. Consequently, we did not observe any significant effect of brain Zhx2 overexpression on OXY reward as measured via conditioned place preference (CPP). However, Zhx2 overexpression did protect against OXY-induced weight loss in females following a high-dose OXY regimen. Despite the effect on weight loss, Zhx2 overexpression had no effect on spontaneous or naloxone-precipitated withdrawal behaviors. We then examined native Zhx2 protein expression in the brains of the BALB/cByJ substrain (showing wild-type levels of Zhx2 expression) via immunohistochemical co-localization and found that Zhx2 is mainly expressed in neurons located in key reward, motivational, and emotion-related regions such as the hippocampus (HPC), amygdala, striatum (Str), and cerebellum. To summarize, Zhx2 overexpression via retro-orbital AAV administration was quite limited, yet had significant effects on opioid-induced weight loss. Furthermore, for the first time, we provide anatomical visualization of Zhx2 expression at the protein level in neurons vs. glia throughout multiple brain regions.

bioRxiv (Cold Spring Harbor Laboratory)
Northeastern University (US)
Neurotransmitter Receptor Influence on Behavior
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon